|
WO2019195609A2
(en)
|
2018-04-04 |
2019-10-10 |
Arvinas Operations, Inc. |
Modulators of proteolysis and associated methods of use
|
|
CA3211725A1
(en)
*
|
2021-03-17 |
2022-09-22 |
Tao Jiang |
Pyrimidine-fused cyclic compound, preparation method therefor and use thereof
|
|
EP4361157A4
(en)
*
|
2021-06-21 |
2024-10-16 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
FUSED TETRACYCLIC COMPOUND, ITS PREPARATION METHOD AND ITS USE IN MEDICINE
|
|
AU2022303440A1
(en)
*
|
2021-07-02 |
2024-02-22 |
Shanghai De Novo Pharmatech Co., Ltd. |
Kras g12d inhibitor and use thereof
|
|
TW202315626A
(zh)
*
|
2021-08-31 |
2023-04-16 |
大陸商勁方醫藥科技(上海)有限公司 |
嘧啶并環類化合物及其製法和用途
|
|
US20250034166A1
(en)
*
|
2021-09-27 |
2025-01-30 |
Jacobio Pharmaceuticals Co., Ltd. |
Polycyclic fused ring derivatives and use thereof
|
|
WO2023103906A1
(zh)
*
|
2021-12-07 |
2023-06-15 |
贝达药业股份有限公司 |
Kras g12d抑制剂及其在医药上的应用
|
|
EP4471037A1
(en)
*
|
2022-01-30 |
2024-12-04 |
Shanghai Pharmaceuticals Holding Co., Ltd. |
Quinoline compound and use thereof
|
|
JP2025510572A
(ja)
|
2022-03-08 |
2025-04-15 |
レボリューション メディシンズ インコーポレイテッド |
免疫不応性肺癌を治療するための方法
|
|
EP4491673A4
(en)
*
|
2022-03-08 |
2026-03-18 |
Shinetsu Chemical Co |
TWO-COMPONENT ADDITION-CURDED THERMOCONDUCTIVE SILICONE COMPOSITION, AND A HARDENED SILICONE OBJECT THEREIN
|
|
CR20240508A
(es)
|
2022-05-19 |
2024-12-20 |
Genentech Inc |
Compuestos aza-tetracíclicos de oxazepina y usos de los mismos
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
TW202408520A
(zh)
*
|
2022-07-08 |
2024-03-01 |
大陸商貝達藥業股份有限公司 |
Kras g12d抑制劑及其在醫藥上的應用
|
|
CN117430620A
(zh)
*
|
2022-07-22 |
2024-01-23 |
上海医药集团股份有限公司 |
嘧啶环类化合物、其中间体、其药物组合物及其应用
|
|
WO2024022444A1
(zh)
|
2022-07-27 |
2024-02-01 |
江苏恒瑞医药股份有限公司 |
稠环类化合物、其制备方法及其在医药上的应用
|
|
IL318647A
(en)
|
2022-08-05 |
2025-03-01 |
Kumquat Biosciences Inc |
Heterocyclic compounds and their uses
|
|
WO2024041621A1
(en)
*
|
2022-08-25 |
2024-02-29 |
Jacobio Pharmaceuticals Co., Ltd. |
K-ras mutant protein inhibitors
|
|
WO2024041573A1
(en)
*
|
2022-08-25 |
2024-02-29 |
Zai Lab (Shanghai) Co., Ltd. |
Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof
|
|
WO2024051721A1
(en)
*
|
2022-09-07 |
2024-03-14 |
Nikang Therapeutics, Inc. |
Tetracyclic derivatives as kras inhibitors
|
|
WO2024138486A1
(en)
*
|
2022-12-29 |
2024-07-04 |
Nikang Therapeutics, Inc. |
Tetracyclic derivatives as kras inhibitors
|
|
CN119923401A
(zh)
*
|
2022-09-23 |
2025-05-02 |
伊迪恩斯股份有限公司 |
新型四杂环化合物
|
|
TW202426459A
(zh)
*
|
2022-09-23 |
2024-07-01 |
大陸商勁方醫藥科技(上海)有限公司 |
嘧啶并環類化合物及其製法和用途
|
|
AU2023388747A1
(en)
*
|
2022-12-07 |
2025-07-10 |
Jacobio Pharmaceuticals Co., Ltd. |
Fused cyclic compounds and use thereof
|
|
WO2024149214A1
(en)
*
|
2023-01-10 |
2024-07-18 |
Nikang Therapeutics, Inc. |
Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway
|
|
WO2024153119A1
(en)
*
|
2023-01-18 |
2024-07-25 |
Suzhou Zanrong Pharma Limited |
Kras g12d inhibitors and uses thereof
|
|
WO2024153180A1
(zh)
*
|
2023-01-18 |
2024-07-25 |
上海艾力斯医药科技股份有限公司 |
杂环类化合物、其药物组合物及其用途
|
|
WO2024153116A1
(en)
*
|
2023-01-18 |
2024-07-25 |
Suzhou Zanrong Pharma Limited |
Kras g12d inhibitors and uses thereof
|
|
US12448399B2
(en)
|
2023-01-26 |
2025-10-21 |
Arvinas Operations, Inc. |
Cereblon-based KRAS degrading PROTACs and uses related thereto
|
|
WO2024178304A1
(en)
*
|
2023-02-24 |
2024-08-29 |
Alterome Therapeutics, Inc. |
Kras modulators
|
|
AU2024241633A1
(en)
|
2023-03-30 |
2025-11-06 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
CR20250420A
(es)
|
2023-04-07 |
2025-11-20 |
Revolution Medicines Inc |
Inhibidores macrocíclicos de ras
|
|
AR132338A1
(es)
|
2023-04-07 |
2025-06-18 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
CN121464140A
(zh)
|
2023-04-14 |
2026-02-03 |
锐新医药公司 |
Ras抑制剂的结晶形式、含有其的组合物及其使用方法
|
|
CN121100123A
(zh)
|
2023-04-14 |
2025-12-09 |
锐新医药公司 |
Ras抑制剂的结晶形式
|
|
TW202508595A
(zh)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
用於ｒａｓ相關疾病或病症之組合療法
|
|
WO2024243186A2
(en)
*
|
2023-05-22 |
2024-11-28 |
Board Of Regents, The University Of Texas System |
Heterocyclic compounds as nras inhibitors
|
|
TW202517649A
(zh)
*
|
2023-07-18 |
2025-05-01 |
大陸商泰勵生物科技（上海）有限公司 |
具有抗ｋｒａｓ突變腫瘤活性的化合物
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
CN117430564A
(zh)
*
|
2023-10-18 |
2024-01-23 |
爱斯特（成都）生物制药股份有限公司 |
一种7-溴-2,6-二氯-5,8-二氟噻唑啉-4(3h)-酮的制备方法
|
|
WO2025111586A1
(en)
*
|
2023-11-22 |
2025-05-30 |
Genentech, Inc. |
Polymorphs of and synthetic process for an aza-tetracyclic oxazepine inhibitor of kras-g12d
|
|
CN119490512A
(zh)
*
|
2024-01-26 |
2025-02-21 |
苏州盛迪亚生物医药有限公司 |
一种苯并噻吩取代稠环化合物的可药用盐、其结晶形式及用途
|
|
CN119661556B
(zh)
*
|
2024-01-26 |
2025-12-09 |
苏州盛迪亚生物医药有限公司 |
一种稠环类化合物的可药用盐、其结晶形式及用途
|
|
CN119684315A
(zh)
*
|
2024-01-26 |
2025-03-25 |
苏州盛迪亚生物医药有限公司 |
一种苯并噻吩取代稠环化合物的结晶形式及其制备方法
|
|
WO2025157261A1
(zh)
*
|
2024-01-26 |
2025-07-31 |
江苏恒瑞医药股份有限公司 |
G12d抑制剂化合物晶型及其制备方法
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025209456A1
(zh)
*
|
2024-04-03 |
2025-10-09 |
北京泰德制药股份有限公司 |
血管紧张素ii 2型受体拮抗剂及其用于治疗癌性疼痛的用途
|
|
WO2025218798A1
(zh)
*
|
2024-04-19 |
2025-10-23 |
领泰生物医药(绍兴)有限公司 |
Kras g12d降解剂及其制备方法和应用
|
|
TW202547461A
(zh)
|
2024-05-17 |
2025-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025256655A1
(zh)
*
|
2024-06-14 |
2025-12-18 |
上海翰森生物医药科技有限公司 |
一种含嘧啶多元并环类衍生物抑制剂的晶型及其制备方法
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|
|
WO2026073024A1
(en)
*
|
2024-09-30 |
2026-04-02 |
Gilead Sciences, Inc. |
Kras g12d inhibitors for the treatment of cancer
|